Why SIBO Is So Difficult to Diagnose

In 2017, shortly after she turned 32, Phoebe Lapine had just spent the previous three years overhauling her health to make up for her ailing thyroid, the result of unchecked Hashimoto’s thyroiditis. She was following a gluten-free diet, drinking kombucha and taking prebiotics, and finally feeling her best when she noticed peculiar gut symptoms starting to rear their head: burping during meals, stomach discomfort, and a bloated belly that simply would not deflate. She turned to a functional doctor who quickly gave her a diagnosis: small intestinal bacterial overgrowth (SIBO), a gut condition not uncommon for hypothyroid patients.

Lapine, who lives in New York, had never heard of it, nor had her endocrinologist warned of the possibility of developing it. The diagnosis was a relief: “It’s not all in my head; the bloating is just sticking to my body like an inner tube,” Lapine, now 36, remembers thinking. But treatment proved to be an odyssey in and of itself. It would take six weeks of antimicrobial medicines and another six months of a restricted diet for her digestion to feel normal again, and for the bloat to finally go away. Lapine, a food and health writer and chef, chronicled her SIBO journey and shared SIBO-appropriate recipes on her blog and podcast in early 2018. That’s when she learned how lucky she’d been.

“I’ve gotten many, many messages and emails from really sick, desperate people. They reach out from all over the world and are like, ‘No one here where I live knows what this is,’” Lapine says. She answered the first few notes, but when the avalanche didn’t let up, she set up an automatic response with links to online resources.

SIBO is a notoriously underdiagnosed condition, despite research suggesting it may be a chief cause of irritable bowel syndrome (IBS). Approximately 11% of people worldwide suffer from IBS, a “wastebasket diagnosis” many patients with an array of digestive issues are given when doctors can’t pinpoint a more precise cause. Their symptoms can be managed through diet and a handful of supplements and medications, but for a long time, a cure was considered to be out of the question. “People were relegated to ‘learn to live with it.’ When SIBO came along, it really offered some cures and solutions,” says Dr. Nirala Jacobi, a naturopathic doctor whose online platform “The SIBO Doctor” offers courses on the disorder for both practitioners and patients. But although Jacobi and others have led an awareness crusade, many practices fall short when it comes to SIBO diagnosis and treatment. “I still hear from patients every day that they go to the gastroenterologist and it’s still not being recognized,” says Jacobi.

More from TIME

SIBO is the abnormal and prolific growth of either bacteria or archaea—a single-celled organism older than bacteria—in the small intestine. The bacteria or archaea interfere with normal digestion by competing with patients for food. Instead of allowing the small intestine to digest food and release nutrients into the bloodstream, the bacteria or archaea get there first and ferment the food. In the fermentation process, the bacteria release hydrogen, and the archaea release methane, creating the appearance of bloating. Although SIBO has served as the umbrella term for both kinds of overgrowth, experts now prefer to differentiate between them and refer to archaea excess as intestinal methanogen overgrowth, or IMO. Certain bacteria can also produce another gas, hydrogen sulfide, but this type of SIBO does not have its own name. In addition to bloating, fermentation can create a range of IBS issues: usually diarrhea from hydrogen and hydrogen sulfide production, and constipation from methane, although there can be both or neither. Over time, in addition to bowel discomfort, gas production leads to poor fat, carbohydrate, and protein absorption by damaging the intestinal wall lining, creating what’s called “leaky gut.” This also causes vitamin deficiencies, the most acute of which are B-12 deficiencies, leading to weakness and fatigue (and in advanced cases, mental confusion).

Read More: What We Know About Leaky Gut Syndrome

Understanding how and why bacteria or archaea start to overgrow in the small intestine is crucial to treating SIBO and IMO. Although they are digestive disorders, they’re almost always a symptom of another underlying issue: motility dysfunction, or the slow transit of food through the small intestine.

Getting to the root cause

By the time patients call up Dr. David Borenstein’s clinic at Manhattan Integrative Medicine, they’ve consulted three GIs before him, on average, without success. Either treatments were ineffective, or after a temporary reprieve, the SIBO or IMO relapsed. According to some studies, relapse rates are as high as 45%.

“Most of the people who do treat it are gastroenterologists,” says Borenstein, an integrative and functional doctor. “They’ll give you an antibiotic. A lot of the time, it helps, but the SIBO will come right back because they’re not treating the root cause of the problem. ”

Diagnosing SIBO and IMO is simple. A breath test is a noninvasive procedure that measures hydrogen and methane gas levels (hydrogen sulfide too, depending on the kind of test) by having patients blow into plastic tubes or bags every 30 minutes for three hours after ingesting a lactulose substrate. Narrowing down the conditions underlying SIBO and IMO may require a few more tests, but a patient history is the best place to start.

A bad episode of food poisoning—or several—can have damaged the patient’s migrating motor complex (MMC), a system that sweeps the small intestine clean like a dishwasher every 90 minutes and which, if impaired, may leave food debris and bacteria behind, allowing them to multiply. The IBS Smart test looks in the blood for anti-CdtB and anti-vinculin, antibodies produced to fight food poisoning. Their presence can indicate post-infectious IBS and suggest that the MMC has been weakened.

Proton pump inhibitors—a common reflux medication that decreases the amount of acid the stomach produces—can have compromised the stomach’s capacity to kill bacteria. In that case, stomach acid levels should be checked. An underperforming thyroid can have slowed a patient’s MMC, so a full thyroid panel ought to be done. Abdominal surgery—a hysterectomy, a laparoscopy to explore possible endometriosis, a hernia—can have produced scar tissue on the small intestine wall that pinches the intestine and obstructs flow, like a kink in a garden hose. Imaging and further exploration can detect that.

Then a solution can be tailored to the patient. Many involve prescribing a prokinetic agent, a medication that enhances motility.

In the meantime, the excess bacteria and archaea can be eliminated one of three ways. The first option many doctors opt for is a two-week regimen of antibiotics—specifically rifaximin, the first and only U.S. Food and Drug Administration–approved IBS drug, for SIBO, or a combination of rifaximin with either neomycin or metronidazole for IMO, since archaea resist rifaximin alone. For a gentler approach, some practitioners prefer to prescribe herbal antimicrobials such as allicin, oregano, berberine, neem, and cinnamon for four to six weeks. For especially recalcitrant cases, some resort to the elemental diet, a liquid formula of predigested nutrients that gives the digestive tract a break, starving the bacteria or archaea in the process. The elemental diet is the nuclear option, as it’s the most challenging one for patients, considering they can’t eat solid food or drink anything besides water for two to three weeks.

A medical and holistic alliance

The origins of SIBO research trace back to our improved understanding of the microbiome and, specifically, to advances presented by Dr. Mark Pimentel, a gastroenterologist and executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai Medical Center. In 1999—before the term microbiome had even gone mainstream—Pimentel published a paper showing that IBS was not a psychological disorder, as was commonly believed at the time; rather, it was the result of bacterial dysbiosis, or an imbalance of the gut’s microbial community.

Pimentel and his team at Cedars-Sinai have spent the past two decades characterizing the major bacteria in the small intestine. Last year, they published a paper that showed the sequences of the microbiome in the duodenum, the jejunum, the ileum and the colon for the first time. And they homed in on SIBO as an important contributing factor to IBS.

Pimentel’s research caught the attention of Allison Siebecker, a naturopathic physician who had been conducting her own SIBO research and leading awareness campaigns in the holistic community. In 2010, she became one of the first SIBO experts to create an online resource, SIBOinfo.com, with information about the disorder for both physicians and patients. She invited Pimentel to speak at the 2015 SIBO Symposium, an annual conference she’d started organizing a year prior, where the leading U.S. SIBO researchers presented their findings on the disorder and treatments. Pimentel and Siebecker have continued to collaborate since then.

“What’s interesting in the naturopathic community is that they tend to see patients that a lot of Western physicians aren’t able to sort out, and I think that was the case for IBS and SIBO in the beginning,” Pimentel says. “The naturopathic community was seeing a lot of these patients and then also recognizing the treatments sooner than Western medicine.”

While Pimentel pioneered the use of rifaximin as both an IBS and a SIBO treatment, naturopaths like Siebecker had already been touting herbal antimicrobials as an equally effective treatment method.

More awareness

Medical schools are beginning to include more material on the microbiome and dysbiosis, but practicing doctors may not have received that education.

“I trained to be a doctor 20 years ago, and at the time, SIBO was not known,” explains Dr. Ana Esteban, an intensive-care doctor who now specializes in SIBO. “No one talked about the microbiome. So my generation is training the next generation of doctors. Professionals like me are informing ourselves, but we have to specialize on our own, paying for courses out of pocket, finding the time and resources, because we want to. There’s no institutional help.”

As more online resources like Siebecker’s and Jacobi’s crop up, patients are increasingly turning down wastebasket diagnoses and seeking out doctors who will truly probe their digestive issues.

“A lot of people are still told to eat fiber and learn to live with their IBS,” says Jacobi. “Now because of the Internet and social media, people are just not willing to put up with that anymore and are looking for answers.”

Contact us at [email protected].

Small Intestinal Bacterial Overgrowth – PMC

1. Fine D, Schiller LR. American Gastroenterological Association Medical Position Statement. Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1464–1486. [PubMed] [Google Scholar]

2. Corrazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth: reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98:302–309. [PubMed] [Google Scholar]

3. Issacs PE, Kim YS. Blind loop syndrome and small bowel bacterial contamination. Clin Gastroenterol. 1983;12:395–414. [PubMed] [Google Scholar]

4. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999;94:1327–1331. [PubMed] [Google Scholar]

5. Parlesak A, Klein B, Schecher K, et al. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J Am Geriatr Soc. 2003;51:768–773. [PubMed] [Google Scholar]

6. Mitsui T, Kagami H, Kinomoto H, et al. Small bowel bacterial overgrowth and rice malabsorption in healthy and physically disabled older adults. J Hum Nutr Dietet. 2003;16:119–122. [PubMed] [Google Scholar]

7. Teo M, Chung S, Chitti L, et al. Small bowel bacterial overgrowth is a common cause of chronic diarrhea. J Gastro Hepatol. 2004;19:904–909. [PubMed] [Google Scholar]

8. Lewis SJ, Potts LF, Malhotra R, et al. Small bowel bacterial overgrowth in subjects living in residential care homes. Age Ageing. 1999;28:181–185. [PubMed] [Google Scholar]

9. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419. [PubMed] [Google Scholar]

10. Riordan SM, McIver CJ, Wakefield D, et al. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol. 2001;96:494–500. [PubMed] [Google Scholar]

11. Haboubi NY, Lee GS, Montgomery RD. Duodenal mucosal morphometry of elderly patients with small intestinal bacterial overgrowth: Response to antibiotics treatment. Age Ageing. 1991;20:29–32. [PubMed] [Google Scholar]

12. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106:615–623. [PubMed] [Google Scholar]

13. Husebye E, Skar V, Hoverstad T, et al. Fasting hypochlorhydria with gram positive gastric flora is highly prevalent in healthy old people. Gut. 1992;33:1331–1337. [PMC free article] [PubMed] [Google Scholar]

14. Iivonen MK, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. Scan J Gastroenterol. 1998;33:63–70. [PubMed] [Google Scholar]

15. Brandi G, Biavati B, Calabrese C, et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol. 2006;101:1756–1761. [PubMed] [Google Scholar]

16. Shindo K, Fukumura M. Effect of h3-receptor antagonists on bile acid metabolism. J Investig Med. 1995;43:170–177. [PubMed] [Google Scholar]

17. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54–59. [PMC free article] [PubMed] [Google Scholar]

18. Lewis SJ, Franco S, Young G, et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10:557–561. [PubMed] [Google Scholar]

19. Vantrappen G, Janssens J, Hellemans J, et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59:1158–1166. [PMC free article] [PubMed] [Google Scholar]

20. Stotzer PO, Bjornsson ES, Abrahamsson H. Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scan J Gastroenterol. 1996;31:875–880. [PubMed] [Google Scholar]

21. Husebye E, Skar V, Hoverstad T, et al. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology. 1995;109:1078–1089. [PubMed] [Google Scholar]

22. Lacy BE, Koch KL, Crowell MD. Manometry. In: Schuster MM, Crowell MD, Koch KL, editors. Atlas of Gastrointestinal Motility. 2nd ed. Hamilton, B.C.: Decker; 2002. pp. 135–150. [Google Scholar]

23. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–1622. [PubMed] [Google Scholar]

24. Nieuwenhuijs VB, Verheem A, Van Duijvenbode-Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228:188–193. [PMC free article] [PubMed] [Google Scholar]

25. Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98:1362–1370. [PubMed] [Google Scholar]

26. Strid H, Simren M, Stotzer PO, et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67:129–137. [PubMed] [Google Scholar]

27. Wegener M, Adamek RJ, Wedmann B, et al. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci. 1994;39:2209–2215. [PubMed] [Google Scholar]

28. Kaye SA, Lim SG, Taylor M, et al. Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Brit J Rheumatol. 1995;34:265–269. [PubMed] [Google Scholar]

29. Armbrecht U, Lundell L, Lindstedt G, et al. Causes of malabsorption after total gastrectomy with Roux-en-Y reconstruction. Acta Chir Scand. 1988;154:37–41. [PubMed] [Google Scholar]

30. Akhrass R, Yaffe MB, Fischer C, et al. Small-bowel diverticulosis: perceptions and reality. J Am Coll Surg. 1997;184:383–388. [PubMed] [Google Scholar]

31. Swan RW. Stagnant loop syndrome resulting from small-bowel irradiation injury and intestinal by-pass. Gynecol Oncol. 1974;8:441–445. [PubMed] [Google Scholar]

32. Castiglione F, Del Vecchio Blanco G, Rispo A, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn’s disease. J Clin Gastroenterol. 2000;31:63–66. [PubMed] [Google Scholar]

33. Pignata C, Budillon G, Monaco G, et al. Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes. Gut. 1990;31:879–882. [PMC free article] [PubMed] [Google Scholar]

34. Riordan SM, McIver CJ, Wakefield D, et al. Serum immunoglobulin and soluble IL-2 receptor levels in small intestinal overgrowth with indigenous gut flora. Dig Dis Sci. 1999;44:939–944. [PubMed] [Google Scholar]

35. Riordan SM, McIver CJ, Wakefield D, et al. Small intestinal bacterial overgrowth in the symptomatic elderly. Am J Gastroenterol. 1997;92:47–51. [PubMed] [Google Scholar]

36. McLoughlin GA, Hede JE, Temple JG, et al. The role of IgA in the prevention of bacterial colonization of the jejunum in the vagotomized subject. Br J Surg. 1978;65:435–437. [PubMed] [Google Scholar]

37. Wilcox CM, Waites KB, Smith PD. No relationship between gastric pH, small bowel bacterial colonization, and diarrhoea in HIV-1 infected patients. Gut. 1999;44:101–105. [PMC free article] [PubMed] [Google Scholar]

38. Lacy BE, DeLee R. Irritable Bowel Syndrome: A syndrome in evolution. J Clin Gastroenterol. 2005;39:S230–S242. [PubMed] [Google Scholar]

39. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms in irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506. [PubMed] [Google Scholar]

40. Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose, and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21:1391–1395. [PubMed] [Google Scholar]

41. Parisi G, Leandro G, Bottona E, et al. Small intestinal bacterial overgrowth and irritable bowel syndrome [letter] Am J Gastroenterol. 2003;98:2572. [PubMed] [Google Scholar]

42. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose h3 breath test: Comparison with the 14C-d-xylose and healthy controls. Am J Gastroenterol. 2005:1566–1570. [PubMed] [Google Scholar]

43. Pimentel M, Sofler EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639–2643. [PubMed] [Google Scholar]

44. Virally-Monod M, Tielmans D, Kevorkian JP, et al. Chronic diarrhea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth. Diabetes Metab. 1998;24:530–536. [PubMed] [Google Scholar]

45. Urita Y, Ishihara S, Akimoto T, et al. Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth. World J Gastroenterol. 2006;12:3092–3095. [PMC free article] [PubMed] [Google Scholar]

46. Husebye E, Engedal K. The patterns of motility are maintained in the human small intestine throughout the process of aging. Scand J Gastroenterol. 1992;27:397–404. [PubMed] [Google Scholar]

47. Melkersson M, Andersson H, Bosaeus I, et al. Intestinal transit time in constipated and non-constipated geriatric patients. Scand J Gastroenterol. 1983;18:593–597. [PubMed] [Google Scholar]

48. Tursi A. Gastrointestinal motility disturbances in celiac disease. J Clin Gastroenterol. 2004;38:642–645. [PubMed] [Google Scholar]

49. Tursi A, Brandimarte G, Giorgetti GM. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol. 2003;98:839–843. [PubMed] [Google Scholar]

50. Deitch EA, Sittig K, Li M, et al. Obstructive jaundice promotes bacterial translocation from the gut. Am J Surg. 1990;159:79–84. [PubMed] [Google Scholar]

51. Madrid AM, Cumsille F, Defillippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci. 1997;42:738–742. [PubMed] [Google Scholar]

52. Chang CS, Chen GH, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28:1187–1190. [PubMed] [Google Scholar]

53. Morencos FC, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1995;40:1252–1256. [PubMed] [Google Scholar]

54. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96:2962–2967. [PubMed] [Google Scholar]

55. Bauer TM, Schwacha H, Steinbruckner B, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol. 2002;97:2364–2370. [PubMed] [Google Scholar]

56. Chang CS, Yang SS, Kao CH, et al. Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis. Scand J Gastroenterol. 2001;36:92–96. [PubMed] [Google Scholar]

57. Li YF, Newton TJ, Weisbrodt NW, et al. Intestinal migrating myoelectrical complexes in rats with acute pancreatitis and bile duct ligation. J Surg Res. 1993;55:182–187. [PubMed] [Google Scholar]

58. Van Felius ID, Akkermans LMA, Bosscha K, et al. Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis. Neurogastroenterol Motil. 2003;15:267–276. [PubMed] [Google Scholar]

59. Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin. 1999;15:47–52. [PubMed] [Google Scholar]

60. Hauge T, Persson J, Danielsson D. Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics (heavy drinkers) Digestion. 1997;58:591–595. [PubMed] [Google Scholar]

61. Stotzer PO, Johansson C, Mellstrom D, et al. Bone mineral density in patients with small intestinal bacterial overgrowth. Hepatogastroenterology. 2003;50:1415–1418. [PubMed] [Google Scholar]

62. Saltzman JR, Russell RM. Nutritional consequences of intestinal bacterial overgrowth. Comp Ther. 1994;20:523–530. [PubMed] [Google Scholar]

63. Shindo K, Machinda M, Koide K, et al. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology. 1998;45:1643–1650. [PubMed] [Google Scholar]

64. Wanitschke R, Ammon HV. Effects of dihydroxy bile acids and hydroxyl fatty acids on the absorption of oleic acid in the human jejunum. J Clin Invest. 1978;61:178–186. [PMC free article] [PubMed] [Google Scholar]

65. Gianella RA, Rout WR, Toskes PP. Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome. Gastroenterology. 1974;67:965–974. [PubMed] [Google Scholar]

66. King CE, Toskes PP. Protein-losing enteropathy in the human and experimental rat blind-loop syndrome. Gastroenterology. 1981;80:504–509. [PubMed] [Google Scholar]

67. Welkos SL, Toskes PP, Baer H. Importance of anaerobic bacteria in the cobalamin malabsorption of the experimental rat blind loop syndrome. Gastroenterology. 1981;80:313–320. [PubMed] [Google Scholar]

68. Suter PM, Golner BB, Goldin BR, et al. Reversal of protein-bound vitamin B12 malabsorption with antibiotics in atrophic gastritis. Gastroenterology. 1991;101:1039–1045. [PubMed] [Google Scholar]

69. Russell RM, Krasinski SD, Samloff IM, et al. Folic acid malabsorption in atrophic gastritis: Possible compensation by bacterial folate synthesis. Gastroenterology. 1986;91:1476–1482. [PubMed] [Google Scholar]

70. Camilo E, Zimmerman J, Mason JB, et al. Folate synthesized by bacteria in the human upper small intestine is assimilated by the host. Gastroenterology. 1996;110:991–998. [PubMed] [Google Scholar]

71. Romagnuolo J, Schiller, D, Bailey, RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol. 2002;97:1113–1126. [PubMed] [Google Scholar]

72. Riordan SM, McIver CJ, Duncombe VM, et al. Evaluation of the rice breath hydrogen test for small intestinal bacterial overgrowth. Am J Gastroenterol. 2000;95:2858–2864. [PubMed] [Google Scholar]

73. King CE, Toskes PP, Guilarte TR, et al. Comparison of the one-gram d-[14C]xylose breath test to the [14C]bile acid breath test in patients with small-intestine bacterial overgrowth. Dig Dis Sci. 1980;25:53–58. [PubMed] [Google Scholar]

74. Swart GR, van den Berg JW. 13C breath tests in gastroenterological practice. Scand J Gastroenterol Suppl. 1998;225:13–18. [PubMed] [Google Scholar]

75. King CE, Toskes PP. Comparison of the 1 gram 14C-D-xylose, 10 gram lactulose and 80 gram glucose h3 breath test in patients with small intestinal bacterial overgrowth. Gastroenterology. 1986;91:1447–1451. [PubMed] [Google Scholar]

76. Fromm H, Hofmann AF. Breath test for altered bile-acid metabolism. Lancet. 1971;2:621–625. [PubMed] [Google Scholar]

77. Suhr O, Danielsson A, Horstedt P, et al. Bacterial contamination of the small bowel evaluated by breath tests, ⁷⁵Se-labelled homocholic-tauro acid, and scanning electron microscopy. Scan J Gastroenterol. 1990;25:841–852. [PubMed] [Google Scholar]

78. Gibson GR, Cummings JH, Macfarlane GT, et al. Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut. 1990;31:679–683. [PMC free article] [PubMed] [Google Scholar]

79. Bjorneklett A, Fausa O, Midvedt T. Small-bowel bacterial overgrowth in the postgastrectomy syndrome. Scan J Gastroenterol. 1983;18:277–287. [PubMed] [Google Scholar]

80. Salzberg DM, Levine GM, Lubar C. Impact of age, sex, race, and functional complaints on hydrogen (h3) production. Dig Dis Sci. 1988;33:308–314. [PubMed] [Google Scholar]

81. Hutchinson S, Logan R. The effect of long-term omeprazole on the glucosehydrogen breath test in elderly patients. Age Ageing. 1997;26:87–89. [PubMed] [Google Scholar]

82. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95:982–988. [PubMed] [Google Scholar]

83. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose breath test: comparison with ¹⁴C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566–1570. [PubMed] [Google Scholar]

84. Rumessen JJ, Gudmand-Hoyer E, Bachmann E, et al. Diagnosis of bacterial overgrowth of the small intestine. Comparison of the ¹⁴C-D-xylose breath test and jejunal cultures in 60 patients. Scand J Gastroenterol. 1985;20:1267–1275. [PubMed] [Google Scholar]

85. Stotzer PO, Kilander AF. Comparison of the 1-gram ¹⁴C-D-xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. Digestion. 2000;61:165–171. [PubMed] [Google Scholar]

86. Goshal UC, Goshal U, Das K, et al. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome, and its relationship with oro-cecal transit time. Indian J Gastroenterol. 2006;25:6–10. [PubMed] [Google Scholar]

87. Riordan SM, McIver CJ, Walker BM, et al. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol. 1996;91:1795–1803. [PubMed] [Google Scholar]

88. Chang CS, Chen GH, Kao CH, et al. Increased accuracy of the carbon-14 Dxylose breath test in detecting small-intestinal bacterial overgrowth by correction with the gastric emptying rate. Eur J Nucl Med. 1995;22:1118–1122. [PubMed] [Google Scholar]

89. Perman JA, Modler S, Barr RG, et al. Fasting breath hydrogen concentration: normal values and clinical application. Gastroenterology. 1984;87:1358–1363. [PubMed] [Google Scholar]

90. Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cis-apride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96:1251–1255. [PubMed] [Google Scholar]

91. Edmunds MC, Chen JD, Soykan I, et al. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998;12:167–174. [PubMed] [Google Scholar]

92. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461–1467. [PubMed] [Google Scholar]

93. Bishop WP. Breath hydrogen testing for small bowel bacterial overgrowth– a lot of hot air? J Pediatr Gastroenterol Nutr. 1997;25:245–246. [PubMed] [Google Scholar]

94. Di Stefano M, Miceli E, Missanelli A, et al. Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Aliment Pharmacol Ther. 2005;21:985–992. [PubMed] [Google Scholar]

95. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14:551–556. [PubMed] [Google Scholar]

96. Castiglione F, Rispo A, Di Girolamo E, et al. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;18:1107–1112. [PubMed] [Google Scholar]

97. Attar A, Flourie B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 1999;117:794–797. [PubMed] [Google Scholar]

98. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;92:412–419. [PubMed] [Google Scholar]

99. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (Rifaxamin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145:557–563. [PubMed] [Google Scholar]

100. Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina. 2002;62:159–163. [PubMed] [Google Scholar]

101. Stotzer PO, Blomberg L, Conway PL, et al. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD.